|
Synonyms: DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak®
denileukin diftitox is an approved drug (FDA (1999))
Compound class:
Peptide
Comment: Denileukin diftitox is an anti-cancer immunotherapy drug that was designed to target and eradicate malignant (IL-2 receptor-expressing) T cells. It is a recombinant protein containing peptide sequences of both interleukin-2 and diphtheria toxin [1,5]. It simultaneously directly kills IL-2R expressing tumour cells and promotes depletion of host Treg cells which enhances the immune response
|
Classification  |
|
| Compound class | Peptide |
| Approved drug? | Yes (FDA (1999)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 7680 | denileukin diftitox |
| Synonyms |
| DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 704 |
| Other databases | |
| CAS Registry No. | 173146-27-5 (source: SciFinder) |
| ChEMBL Ligand | CHEMBL1201550 |
| DrugBank Ligand | DB00004 |
| GtoPdb PubChem SID | 178103623 |
| Search PubMed clinical trials | denileukin diftitox |
| Search PubMed titles | denileukin diftitox |
| Search PubMed titles/abstracts | denileukin diftitox |
| Wikipedia | Denileukin_diftitox |
